Description: ReNeuron Group plc develops and sells cell-based therapies in the United Kingdom. The company's lead therapeutic candidate is CTX stem cell therapy, which has been completed Phase II clinical trial for the treatment of patients living with chronic disability following stroke, as well as that has been completed Phase I clinical trial to treat limb ischaemia. It is also involved in developing human retinal progenitor cell candidate, which is in Phase I/II clinical trial for the treatment of retinitis pigmentosa, a blindness-causing disease of the retina, as well as that is in Phase I clinical trial to treat cone-rod dystrophy, an inherited eye disorder; and CTX-derived exosomes, which are nanoparticles released by cells containing various active proteins and microRNAs. ReNeuron Group plc was founded in 1997 and is headquartered in Pencoed, the United Kingdom.
Home Page: www.reneuron.com
Pencoed Business Park
Pencoed,
CF35 5HY
United Kingdom
Phone:
44 20 3819 8400
Officers
| Name | Title |
|---|---|
| Mr. Iain Gladstone Ross B.Sc., BSc (Hons), C.DIR, CH.D | Executive Chairman |
| Mr. John Michael Hawkins A.C.A. | Company Secretary, CFO & Director |
| Dr. John David Sinden B.A., BA, M.A., MA, Ph.D. | Co-Founder |
| Ms. Suzanne Hancock | Chief Operations Officer |
| Dr. Randolph Corteling Ph.D. | Chief Scientific Officer |
| Mr. Simon Dew | Chief Business Officer |
Exchange: PINK
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0.0122 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.0207 |
| Price-to-Sales TTM: | 9.7149 |
| IPO Date: | |
| Fiscal Year End: | March |
| Full Time Employees: | 26 |